Solid Biosciences Inc. (SLDB)

Solid Biosciences Inc. (SLDB) Healthcare & Pipeline Overview

Solid Biosciences Inc. is a biotechnology firm specializing in gene therapies for Duchenne muscular dystrophy, with lead candidates SGT-001 and SGT-003 in clinical development. The company's platform technologies, including dual gene expression and novel capsids, aim to improve treatment efficacy and address unmet needs in the DMD market, collaborating with Ultragenyx Pharmaceutical Inc.

What Is the Investment Thesis for SLDB?

Solid Biosciences presents a notable research candidate within the gene therapy space, specifically targeting Duchenne muscular dystrophy (DMD). The company's lead candidate, SGT-001, is in Phase I/II clinical trials, with potential for positive data readouts that could drive significant stock appreciation. The development of SGT-003, a next-generation gene therapy, further strengthens the pipeline. Collaboration with Ultragenyx Pharmaceutical Inc. validates the company's technology and provides financial and development support. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other gene therapy developers in the DMD space. The company's market capitalization is $0.67 billion, and the beta is 2.58, indicating high volatility. Successful clinical development and commercialization of SGT-001 or SGT-003 could lead to substantial revenue growth and market share gains.

Based on FMP financials and quantitative analysis

SLDB Key Highlights

• Lead product candidate SGT-001 is in Phase I/II clinical trials for Duchenne muscular dystrophy (DMD).
• Developing SGT-003, a next-generation gene transfer candidate for DMD.
• Collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for DMD.
• Focus on platform technologies, including dual gene expression and novel capsids, to enhance gene therapy delivery.
• Market capitalization of $878.05M reflects investor sentiment and growth potential in the DMD gene therapy market.

Who Are SLDB's Competitors?

SLDB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SLDB's Key Strengths?

• Proprietary gene therapy platform.
• Collaboration with Ultragenyx.
• Focus on Duchenne muscular dystrophy (DMD).
• Lead product candidate in clinical trials.

What Are SLDB's Weaknesses?

• Limited financial resources compared to larger pharmaceutical companies.
• Dependence on clinical trial outcomes.
• High regulatory hurdles for gene therapy products.
• Competition from other companies developing DMD therapies.

What Could Drive SLDB Stock Higher?

• Data readout from the ongoing Phase I/II clinical trial of SGT-001.
• Initiation of clinical trials for SGT-003.
• Continued progress in the collaboration with Ultragenyx Pharmaceutical Inc.
• Advancements in platform technologies, including dual gene expression and novel capsids.

What Are the Key Risks for SLDB?

• Negative return on equity (-74.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory hurdles and delays in obtaining marketing approval.
• Competition from other companies developing DMD therapies.
• Dependence on key personnel and collaborators.
• Financial risks associated with funding research and development activities.

What Are the Growth Opportunities for SLDB?

• Expansion of SGT-001 Clinical Trials: Solid Biosciences has the opportunity to expand the ongoing Phase I/II clinical trials for SGT-001 to include a larger patient population and additional clinical sites. Positive data from these expanded trials could accelerate regulatory approval and commercialization. The DMD market is estimated to reach $4 billion by 2028, providing a significant revenue opportunity for Solid Biosciences if SGT-001 proves to be effective and safe.
• Advancement of SGT-003 Development: The development of SGT-003, a next-generation gene transfer candidate, represents a key growth opportunity for Solid Biosciences. SGT-003 incorporates advancements in vector design and manufacturing, potentially leading to improved efficacy and safety compared to SGT-001. Successful preclinical and clinical development of SGT-003 could position Solid Biosciences as a leader in DMD gene therapy.
• Strategic Partnerships and Collaborations: Solid Biosciences can pursue additional strategic partnerships and collaborations with pharmaceutical companies, academic institutions, and patient advocacy groups. These partnerships can provide access to new technologies, funding, and expertise, accelerating the development and commercialization of DMD therapies. The collaboration with Ultragenyx Pharmaceutical Inc. serves as a successful example of this strategy.
• Expansion into New DMD Subtypes: Solid Biosciences can explore the potential to expand its gene therapy platform to address different subtypes of DMD. While SGT-001 and SGT-003 are designed to treat a broad range of DMD mutations, there may be specific subtypes that require tailored gene therapy approaches. Developing therapies for these underserved populations could create new market opportunities for Solid Biosciences.
• Development of Novel Delivery Technologies: Solid Biosciences can invest in the development of novel gene therapy delivery technologies, such as improved AAV vectors or non-viral delivery methods. These technologies could enhance the efficiency and safety of gene therapy, potentially leading to more effective treatments for DMD and other genetic disorders. The company's focus on platform technologies, including dual gene expression and novel capsids, supports this growth strategy.

What Opportunities Does SLDB Have?

• Expansion of clinical trials to new patient populations.
• Development of next-generation gene therapy candidates.
• Strategic partnerships and collaborations.
• Expansion into new DMD subtypes.

What Threats Does SLDB Face?

• Clinical trial failures.
• Regulatory delays or rejection.
• Competition from other DMD therapies.
• Patent challenges.

What Are SLDB's Competitive Advantages?

• Proprietary gene therapy platform technologies.
• Strong intellectual property protection for their gene therapy candidates.
• Established collaboration with Ultragenyx Pharmaceutical Inc.
• Expertise in developing gene therapies for Duchenne muscular dystrophy (DMD).

What Does SLDB Do?

Solid Biosciences Inc., founded in 2013 and headquartered in Cambridge, Massachusetts, is a biotechnology company dedicated to developing transformative therapies for Duchenne muscular dystrophy (DMD). DMD is a genetic disorder characterized by progressive muscle degeneration and weakness due to mutations in the dystrophin gene. Solid Biosciences is focused on addressing the underlying genetic cause of DMD through gene therapy approaches. The company's lead product candidate, SGT-001, is an adeno-associated virus (AAV) vector-based gene therapy designed to deliver a functional dystrophin gene to patients' muscles. SGT-001 is currently in Phase I/II clinical trials, aiming to demonstrate its ability to drive functional dystrophin protein expression and improve muscle function in DMD patients. Solid Biosciences is also developing SGT-003, a next-generation gene transfer candidate for DMD, incorporating advancements in vector design and manufacturing. In addition to its lead programs, Solid Biosciences is advancing platform technologies, including dual gene expression, which allows for packaging multiple transgenes into a single vector, and novel capsids, which enhance gene delivery efficiency and tissue specificity. The company has a collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for DMD, leveraging their combined expertise and resources to accelerate the development of innovative treatments for this debilitating disease. Solid Biosciences' mission is to improve the lives of patients with DMD by developing disease-modifying therapies that address the root cause of the condition and provide long-term benefit.

What Products and Services Does SLDB Offer?

• Develop gene therapies for Duchenne muscular dystrophy (DMD).
• Conduct clinical trials to evaluate the safety and efficacy of their gene therapy candidates.
• Advance platform technologies to improve gene therapy delivery and expression.
• Collaborate with pharmaceutical companies to develop and commercialize new therapies.
• Research and develop next-generation gene transfer candidates for DMD.
• Focus on addressing the underlying genetic cause of DMD through gene therapy approaches.
• Develop novel capsids to enhance gene delivery efficiency and tissue specificity.

How Does SLDB Make Money?

• Develop and out-license gene therapy technologies.
• Generate revenue through collaboration agreements with pharmaceutical companies.
• Monetize gene therapy products upon regulatory approval and commercialization.
• Focus on developing proprietary gene therapy platforms and technologies.

What Industry Does SLDB Operate In?

Solid Biosciences operates in the biotechnology industry, specifically within the gene therapy sector. The market for gene therapies is rapidly expanding, driven by advancements in vector technology and increasing success in clinical trials. The Duchenne muscular dystrophy (DMD) market represents a significant unmet need, with limited treatment options available. Solid Biosciences competes with other gene therapy companies, such as Sarepta Therapeutics and Pfizer, who are also developing DMD therapies. The industry is characterized by high R&D costs, regulatory hurdles, and competition for market share. Success in this space requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.

Who Are SLDB's Key Customers?

• Patients with Duchenne muscular dystrophy (DMD).
• Pharmaceutical companies seeking to develop and commercialize DMD therapies.
• Healthcare providers who treat patients with DMD.
• Research institutions and academic centers involved in DMD research.

FY2026 estForward Outlook

Wall Street analysts project Solid Biosciences Inc. revenue of about $3.7M for fiscal 2026, with EPS near $-1.93. The estimate reflects 11 contributing analysts.

SLDB Valuation & Market Position

With a $878.05M market cap, Solid Biosciences Inc. sits in the small-cap segment of the market. Relative to its peer group, SLDB's quantitative score of 49/100 is below the peer average of 67/100.

ROE -74%Key Financial Metrics

Return on equity for Solid Biosciences Inc. stands at -74.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -45.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 13.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Solid Biosciences Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.58 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Solid Biosciences Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Alexander G. Cumbo. SLDB has traded publicly since 2018.

SLDB Financials

SLDB Latest News

SLDB Analyst Consensus

SLDB MoonshotScore

Latest Solid Biosciences Inc. Analysis

Solid Biosciences Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources